We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients

cell-1
cell-2
cell-3
cell-4
cell-5
cell-6

Spotlight

Curis Corporate Presentation

View our Current Corporate Presentation here.

Curis Corporate Presentation

Curis – Emavusertib (IRAK4i)

At Curis, we are developing differentiated therapeutics with the goal of improving the lives of cancer patients. Our new animation shows how Emavusertib (CA-4948) is being developed to target hematologic malignancies and other cancers

Curis - VISTA

Pipeline

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
Emavusertib*
IRAK4
IRAK4-driven Leukemia
(AML/MDS)

TakeAim Leukemia

Emavusertib*
IRAK4
IRAK4-driven Lymphoma
(NHL, CLL, WM)

TakeAim Lymphoma

Fimepinostat
HDAC/PI3K
MYC-altered Cancers

Immune Checkpoint Inhibitors
CA-327*
TIM3/PDL1
PDL1/TIM3-expressing Cancers

CA-170*
VISTA/PDL1
PDL1/VISTA-expressing Cancers

Approved Drug
Erivedge**
Hedgehog
Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
Emavusertib*
IRAK4
IRAK4-driven Leukemia
(AML/MDS)
Clinical Activity
Emavusertib*
IRAK4
IRAK4-driven Lymphoma
(NHL, CLL, WM)
Clinical Activity
Fimepinostat
HDAC/PI3K
MYC-altered CancersClinical Activity
Immune Checkpoint Inhibitors
CA-327*
TIM3/PDL1
PDL1/TIM3-expressing CancersProof of Principle
CA-170*
VISTA/PDL1
PDL1/VISTA-expressing CancersClinical Activity
Approved Drug
Erivedge**
Hedgehog
Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** IP licensed to Genentech (Curis receives royalty income)

Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development.